DMD Bio-Rad Microplate Reader

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Usmani, K. A.
Right arrow Articles by Hodgson, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Usmani, K. A.
Right arrow Articles by Hodgson, E.

Vol. 31, Issue 4, 384-391, April 2003

Inhibition and Activation of the Human Liver Microsomal and Human Cytochrome P450 3A4 Metabolism of Testosterone by Deployment-Related Chemicals

Khawja A. Usmani, Randy L. Rose, and Ernest Hodgson

Department of Environmental and Molecular Toxicology, North Carolina State University, Raleigh, North Carolina

Cytochrome P450 (P450) enzymes are major catalysts involved in the metabolism of xenobiotics and endogenous substrates such as testosterone (TST). Major TST metabolites formed by human liver microsomes include 6beta -hydroxytestosterone (6beta -OHTST), 2beta -hydroxytestosterone (2beta -OHTST), and 15beta -hydroxytestosterone (15beta -OHTST). A screen of 16 cDNA-expressed human P450 isoforms demonstrated that 94% of all TST metabolites are produced by members of the CYP3A subfamily with 6beta -OHTST accounting for 86% of all TST metabolites. Similar Km values were observed for production of 6beta -, 2beta -, and 15beta -OHTST with human liver microsomes (HLM) and CYP3A4. However, Vmax and CLint were significantly higher for 6beta -OHTST than 2beta -OHTST (~18-fold) and 15beta -OHTST (~40-fold). Preincubation of HLM with a variety of ligands, including chemicals used in military deployments, resulted in varying levels of inhibition or activation of TST metabolism. The greatest inhibition of TST metabolism in HLM was following preincubation with organophosphorus compounds, including chlorpyrifos, phorate, and fonofos, with up to 80% inhibition noticed for several metabolites including 6beta -OHTST. Preincubation of CYP3A4 with chlorpyrifos, but not chlorpyrifos-oxon, resulted in 98% inhibition of TST metabolism. Phorate and fonofos also inhibited the production of most primary metabolites of CYP3A4. Kinetic analysis indicated that chlorpyrifos was one of the most potent inhibitors of major TST metabolites followed by fonofos and phorate. Chlorpyrifos, fonofos, and phorate inhibited major TST metabolites noncompetitively and irreversibly. Conversely, preincubation of CYP3A4 with pyridostigmine bromide increased metabolite levels of 6beta -OHTST and 2beta -OHTST. Preincubation of human aromatase (CYP19) with the test chemicals had no effect on the production of the endogenous estrogen, 17beta -estradiol.


Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Toxicol SciHome page
B. W. Cooper, T. M. Cho, P. M. Thompson, and A. D. Wallace
Phthalate Induction of CYP3A4 is Dependent on Glucocorticoid Regulation of PXR Expression
Toxicol. Sci., June 1, 2008; 103(2): 268 - 277.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
K. A. Usmani, T. M. Cho, R. L. Rose, and E. Hodgson
Inhibition of the Human Liver Microsomal and Human Cytochrome P450 1A2 and 3A4 Metabolism of Estradiol by Deployment-Related and Other Chemicals
Drug Metab. Dispos., September 1, 2006; 34(9): 1606 - 1614.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
R. E. Pearce, J. P. Uetrecht, and J. S. Leeder
PATHWAYS OF CARBAMAZEPINE BIOACTIVATION IN VITRO: II. THE ROLE OF HUMAN CYTOCHROME P450 ENZYMES IN THE FORMATION OF 2-HYDROXYIMINOSTILBENE
Drug Metab. Dispos., December 1, 2005; 33(12): 1819 - 1826.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. S. Leeder, R. Gaedigk, K. A. Marcucci, A. Gaedigk, C. A. Vyhlidal, B. P. Schindel, and R. E. Pearce
Variability of CYP3A7 Expression in Human Fetal Liver
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 626 - 635.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.